|Target||B-cell maturation antigen (BCMA) (CD269)|
|Other names||belantamab mafodotin-blmf, GSK2857916|
|Drug class||Antineoplastic agent|
|Chemical and physical data|
Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity.
Belantamab mafodotin was approved for medical use in the United States and in the European Union in August 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
On November 22, 2022, GSK plc announced it initiated the process for withdrawal of the United States marketing authorization for belantamab mafodotin following the request of the U.S. FDA. This request was based on the outcome of the DREAMM-3 phase III confirmatory trial,  which did not meet the requirements of the U.S. FDA Accelerated Approval regulations.
Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
The prescribing information includes a boxed warning stating belantamab mafodotin causes changes in the corneal epithelium resulting in alterations in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes.
Because of the risks of ocular toxicity, belantamab mafodotin is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), called the BLENREP REMS.
Belantamab mafodotin was evaluated in DREAMM-2 (NCT 03525678), an open-label, multicenter trial. Participants received either belantamab mafodotin, 2.5 mg/kg or 3.4 mg/kg intravenously, once every three weeks until disease progression or unacceptable toxicity.
Efficacy was based on overall response rate (ORR) and response duration, as evaluated by an independent review committee using the International Myeloma Working Group uniform response criteria. The ORR was 31% (97.5% CI: 21%, 43%). Seventy-three percent of responders had response durations ≥6 months. These results were observed in participants receiving the recommended dose of 2.5 mg/kg.
Society and culture
- "Blenrep- belantamab injection, powder, lyophilized, for solution". DailyMed. 5 August 2020. Retrieved 11 August 2020.
- "Blenrep EPAR". European Medicines Agency (EMA). 23 July 2020. Retrieved 24 September 2020.
- "FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma". U.S. Food and Drug Administration (FDA). 5 August 2020. Retrieved 6 August 2020. This article incorporates text from this source, which is in the public domain.
- "FDA Approves GSK's BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma" (Press release). GlaxoSmithKline. 6 August 2020. Retrieved 6 August 2020 – via Business Wire.
- "New Drug Therapy Approvals 2020". U.S. Food and Drug Administration (FDA). 31 December 2020. Retrieved 17 January 2021.
- "Drug Approval Package: Blenrep". U.S. Food and Drug Administration (FDA). 1 August 2020. Retrieved 17 January 2021.
- "GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization". GSK. Retrieved 23 November 2022.
- "GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma". GSK. Retrieved 23 November 2022.
- World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80". WHO Drug Information. 32 (3): 431–2. hdl:10665/330907. License: CC BY-NC-SA 3.0 IGO.
- Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, et al. (March 2019). "Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study". Blood Cancer J. 9 (4): 37. doi:10.1038/s41408-019-0196-6. PMC 6426965. PMID 30894515.
- Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, et al. (February 2020). "Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study". Lancet Oncol. 21 (2): 207–221. doi:10.1016/S1470-2045(19)30788-0. PMID 31859245. S2CID 209425201.
- "Belantamab mafodotin". Drug Information Portal. U.S. National Library of Medicine.
- "Belantamab mafodotin". NCI Drug Dictionary. National Cancer Institute.
- Clinical trial number NCT03525678 for "A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody" at ClinicalTrials.gov